Rep. Grace Meng

Healthcare Workforce Resilience Act This bill makes previously unused immigrant visas available to nurses and physicians who petition for such a visa before the date that is 90 days after the end of the declared national emergency relating to the COVID-19 (i.e., coronavirus disease 2019) outbreak. The number of visas available shall be the total number of unused employment-based immigrant visas from FY1992-FY2020, up to 40,000. Of such visas, 25,000 shall be reserved for nurses and 15,000 for physicians. Certain family members may accompany the principal beneficiary of a visa provided under this bill, and visas for such family members shall (1) be made available from the unused visas from FY1992-FY2020, and (2) not be counted against the 40,000 cap. Visas provided under this bill shall be exempt from per-country limitations.

Dignity for Detained Immigrants Act of 2021 This bill directs the Department of Homeland Security (DHS) to establish standards for facilities holding aliens in its custody, phases out using non-DHS facilities for such purposes, and contains other related provisions. The standards shall comply with the American Bar Association's Civil Immigration Detention Standards. The DHS Office of Inspector General (OIG) shall conduct periodic unannounced inspections of each facility and shall take various actions against noncompliant facilities, including imposing fines, cancelling contracts, and closing facilities. DHS shall report to Congress any death of an alien in its custody within 24 hours and conduct an investigation within 30 days that identifies policy changes that could reduce the likelihood of such a death. DHS is prohibited from entering into contracts for third parties to operate detention facilities or alternatives to detention programs and shall terminate existing contracts within three years of the bill's enactment. The bill establishes that OIG facility inspection reports and contracts for an outside entity to operate a detention facility are records available to the public under the Freedom of Information Act. DHS shall maintain certain information relating to detained aliens, including the alien's location and whether the alien was separated from family. The bill provides for various requirements and procedures related to detaining aliens, including (1) prohibiting DHS from detaining children, (2) imposing a presumption that an alien should be released, and (3) establishing that aliens in custody shall be subject to the least restrictive conditions. The bill also abolishes mandatory detention for asylum seekers.

Equal Access to Abortion Coverage in Health Insurance Act of 2021 or the EACH Act of 2021 This bill requires federal health care programs to provide coverage for abortion services and requires federal facilities to provide access to those services. The bill also permits qualified health plans to use funds attributable to premium tax credits and reduced cost sharing assistance to pay for abortion services.

PrEP Assistance Program Act This bill establishes a grant program to provide pre-exposure prophylaxis (PrEP) and related services to individuals at no cost. PrEP is medication given to individuals at risk of HIV to reduce their likelihood of contracting the virus. The Department of Health and Human Services must award the grants to state, tribal, and local governments; certain health clinics; and community-based organizations.

Access to Small Business Investor Capital Act This bill allows a registered investment company to exclude from the calculation of acquired fund fees and expenses those incurred indirectly from investment in a business development company. Instead, such fees and expenses may be disclosed in a footnote. Acquired fund fees and expenses is a required line item on a fund's fee schedule that provides the operating expenses of the fund.

United States–Israel Artificial Intelligence Center Act This bill requires the Department of State to establish the United States–Israel Artificial Intelligence Center to leverage the experience, knowledge, and expertise of institutions of higher education and private sector entities in the United States and Israel to develop more robust research and development cooperation in specified areas (e.g., machine learning, object detection, and speech recognition).

Cosmetic Supply Chain Transparency Act of 2021 This bill requires the Food and Drug Administration (FDA) to maintain a list of certain nonfunctional constituents in cosmetics that are harmful to human health or the environment, authorizes the FDA to request from a brand owner (i.e., the entity bringing a cosmetic to market) certain information about a cosmetic's ingredients, and addresses related issues. For each listed nonfunctional constituent, the list must identify the ingredient or cosmetic (or category of ingredient or cosmetic) in which the constituent is known or reasonably expected to be present. The FDA must also (1) establish procedures for petitions to add substances to the list, (2) issue guidance for industry related to testing and detecting such nonfunctional constituents, and (3) establish a committee to provide advice on creating the list and developing the required industry guidance. Within a year of a nonfunctional constituent being added to the list, a supplier of an ingredient or cosmetic must test for that constituent and provide a brand owner the results and other information before selling the ingredient or cosmetic to the brand owner. A supplier of an ingredient or cosmetic must provide additional information about the item upon a brand owner's request. Brand owners must maintain records with information about the suppliers of ingredients and raw materials used in their cosmetics and provide such information to the FDA upon request. The bill also imposes civil penalties for brand owners and suppliers that violate this bill's provisions.

Maddy summaryHR 5537, the Toxic-Free Beauty Act of 2021, bans specific chemicals in cosmetics under federal law. It prohibits the use of substances like certain PFAS (water-repellent chemicals), phthalates (e.g., dibutyl phthalate), formaldehyde, mercury, and specific parabens in cosmetic products. The ban directly affects cosmetic manufacturers, requiring them to reformulate products, and benefits consumers by removing these chemicals from beauty items. The law takes effect on January 1, 2025, with the ban applying to products bearing or containing the listed substances.

Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021 This bill imposes disclosure and labeling requirements on cosmetics products that contain certain ingredients. A cosmetics product that fails to meet such requirements may not be sold. Within two years of this bill's enactment, a cosmetics product's labeling or packaging must indicate the use of any ingredient that (1) is identified on specified lists of harmful or potentially harmful chemicals, such as chemicals identified as carcinogenic to humans by the Environmental Protection Agency or toxic air contaminants under California regulations; or (2) must be disclosed under certain European Union laws and is present in a product above specified concentrations. The Food and Drug Administration must publish and periodically update on its website a list of the ingredients subject to this requirement. Within one year of this bill's enactment, a brand owner (i.e., the entity bringing a cosmetics product to market) must disclose certain information on its website if a cosmetics product contains any fragrance or flavor ingredient that is (1) present in the product above a certain concentration, or (2) subject to this bill's labeling or packaging requirement. The website must disclose the use of the ingredient in question and other information, such as the ingredient's functional purpose. The use of an ingredient subject to this bill's requirements shall not be treated as a confidential trade secret, but the concentration of such an ingredient shall be treated as confidential commercial information.

Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021 This bill imposes labeling requirements on cosmetics intended for professional use, requires research on health issues relating to cosmetics, and addresses related issues. The Food and Drug Administration (FDA) must require (1) the labeling for cosmetics intended for professional use to include the name of each ingredient in descending order of predominance; and (2) the manufacturer, distributor, or seller of such a cosmetic to provide this information on its website. The Occupational Safety and Health Administration must issue a standard requiring each manufacturer or importer selling a cosmetic intended for professional use to (1) obtain or develop a safety data sheet for the cosmetic in various languages; and (2) make the data sheet available to relevant distributors and employers, such as hair salon owners. The standard must also require employers to make the data sheet available to employees exposed to the product and provide to employees versions of the sheet in languages other than English upon request. The FDA must conduct (or award grants for) research into chemicals linked to adverse health effects and most commonly found in cosmetics that are (1) marketed to women and girls of color; or (2) used by professional nail, hair, and beauty salon workers. The FDA must also award grants to support research focused on designing safer cosmetic chemicals, such as those with no inherent toxicity. The FDA must take actions to ensure that cosmetics marketed to women and girls of color are in full compliance with FDA requirements.